When you buy through links on our articles, Future and its syndication partners may earn a commission.

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

It looks like 2025 will be a revolutionary year for INFINOX. The CFD Broker is prepared to continue its remarkable 2024 with even greater expansion, innovation, and trust-building initiatives. The ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

The new Kids First datasets advance our understanding of how genetics contribute to childhood cancers and congenital disorders, opening new doors for prevention and treatment.

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Chief Operating Officer Ryan Fukushima recently sold a significant portion of his holdings in the company, according to a ...